116 related articles for article (PubMed ID: 32463436)
1. Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months: ProgStar Report No. 13.
Schönbach EM; Strauss RW; Muñoz B; Wolfson Y; Ibrahim MA; Birch DG; Zrenner E; Sunness JS; Ip MS; Sadda SR; West SK; Scholl HPN;
JAMA Ophthalmol; 2020 Jul; 138(7):772-779. PubMed ID: 32463436
[TBL] [Abstract][Full Text] [Related]
2. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.
Schönbach EM; Wolfson Y; Strauss RW; Ibrahim MA; Kong X; Muñoz B; Birch DG; Cideciyan AV; Hahn GA; Nittala M; Sunness JS; Sadda SR; West SK; Scholl HPN;
JAMA Ophthalmol; 2017 Jul; 135(7):696-703. PubMed ID: 28542693
[TBL] [Abstract][Full Text] [Related]
3. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.
Strauss RW; Ho A; Muñoz B; Cideciyan AV; Sahel JA; Sunness JS; Birch DG; Bernstein PS; Michaelides M; Traboulsi EI; Zrenner E; Sadda S; Ervin AM; West S; Scholl HP;
Ophthalmology; 2016 Apr; 123(4):817-28. PubMed ID: 26786511
[TBL] [Abstract][Full Text] [Related]
4. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).
Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Cideciyan AV; Audo I; Birch DG; Hariri AH; Nittala MG; Sadda S; West S; Scholl HPN;
JAMA Ophthalmol; 2017 Nov; 135(11):1232-1241. PubMed ID: 29049437
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5.
Strauss RW; Muñoz B; Ho A; Jha A; Michaelides M; Mohand-Said S; Cideciyan AV; Birch D; Hariri AH; Nittala MG; Sadda S; Scholl HPN;
JAMA Ophthalmol; 2017 Jul; 135(7):687-695. PubMed ID: 28542697
[TBL] [Abstract][Full Text] [Related]
6. Multimodal analysis of the Preferred Retinal Location and the Transition Zone in patients with Stargardt Disease.
Verdina T; Greenstein VC; Sodi A; Tsang SH; Burke TR; Passerini I; Allikmets R; Virgili G; Cavallini GM; Rizzo S
Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1307-1317. PubMed ID: 28365912
[TBL] [Abstract][Full Text] [Related]
7. Macular function and morphologic features in juvenile stargardt disease: longitudinal study.
Testa F; Melillo P; Di Iorio V; Orrico A; Attanasio M; Rossi S; Simonelli F
Ophthalmology; 2014 Dec; 121(12):2399-405. PubMed ID: 25097154
[TBL] [Abstract][Full Text] [Related]
8. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease.
Melillo P; Testa F; Rossi S; Di Iorio V; Orrico A; Auricchio A; Simonelli F
Invest Ophthalmol Vis Sci; 2016 Jul; 57(9):OCT247-52. PubMed ID: 27409479
[TBL] [Abstract][Full Text] [Related]
9. Differential Disease Progression in Atrophic Age-Related Macular Degeneration and Late-Onset Stargardt Disease.
Lindner M; Lambertus S; Mauschitz MM; Bax NM; Kersten E; Lüning A; Nadal J; Schmitz-Valckenberg S; Schmid M; Holz FG; Hoyng CB; Fleckenstein M;
Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):1001-1007. PubMed ID: 28288486
[TBL] [Abstract][Full Text] [Related]
10. Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease (SMART) Study: Design and Baseline Characteristics (Report No. 1).
Strauss RW; Kong X; Bittencourt MG; Ho A; Jha A; Schönbach EM; Ahmed MI; Muñoz B; Ervin AM; Michaelides M; Birch DG; Sahel JA; Sunness JS; Zrenner E; Bagheri S; Ip M; Sadda S; West S; Scholl HPN;
Ophthalmic Res; 2019; 61(1):36-43. PubMed ID: 29940588
[TBL] [Abstract][Full Text] [Related]
11. Abnormal Visual Function Outside the Area of Atrophy Defined by Short-Wavelength Fundus Autofluorescence in Stargardt Disease.
Sunness JS; Ifrah A; Wolf R; Applegate CA; Sparrow JR
Invest Ophthalmol Vis Sci; 2020 Apr; 61(4):36. PubMed ID: 32334431
[TBL] [Abstract][Full Text] [Related]
12. Morpho-functional correlation of fundus autofluorescence in Stargardt disease.
Parodi MB; Iacono P; Triolo G; La Spina C; Zucchiatti I; Cicinelli MV; Borrelli E; Manitto MP; Martina E; Bandello F
Br J Ophthalmol; 2015 Oct; 99(10):1354-9. PubMed ID: 25837607
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric Inter-Eye Progression in Stargardt Disease.
Lambertus S; Bax NM; Groenewoud JM; Cremers FP; van der Wilt GJ; Klevering BJ; Theelen T; Hoyng CB
Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6824-6830. PubMed ID: 28002570
[TBL] [Abstract][Full Text] [Related]
14. Visual Acuity Change Over 24 Months and Its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease: ProgStar Study Report No. 10.
Kong X; Fujinami K; Strauss RW; Munoz B; West SK; Cideciyan AV; Michaelides M; Ahmed M; Ervin AM; Schönbach E; Cheetham JK; Scholl HPN;
JAMA Ophthalmol; 2018 Aug; 136(8):920-928. PubMed ID: 29902293
[TBL] [Abstract][Full Text] [Related]
15. Impact of segmentation density on spectral domain optical coherence tomography assessment in Stargardt disease.
Velaga SB; Nittala MG; Jenkins D; Melendez J; Ho A; Strauss RW; Scholl HP; Sadda SR
Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):549-556. PubMed ID: 30613916
[TBL] [Abstract][Full Text] [Related]
16. ULTRAWIDEFIELD AUTOFLUORESENCE IN ABCA4 STARGARDT DISEASE.
Klufas MA; Tsui I; Sadda SR; Hosseini H; Schwartz SD
Retina; 2018 Feb; 38(2):403-415. PubMed ID: 28248825
[TBL] [Abstract][Full Text] [Related]
17. Morpho-functional analysis of Stargardt Disease for reading.
Sasso P; Scupola A; Silvestri V; Amore FM; Abed E; Calandriello L; Grimaldi G; Caporossi A
Can J Ophthalmol; 2017 Jun; 52(3):287-294. PubMed ID: 28576211
[TBL] [Abstract][Full Text] [Related]
18. Visual Acuity Change over 12 Months in the Prospective Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: ProgStar Report Number 6.
Kong X; Strauss RW; Cideciyan AV; Michaelides M; Sahel JA; Munoz B; Ahmed M; Ervin AM; West SK; Cheetham JK; Scholl HPN;
Ophthalmology; 2017 Nov; 124(11):1640-1651. PubMed ID: 28549516
[TBL] [Abstract][Full Text] [Related]
19. Study of Late-Onset Stargardt Type 1 Disease: Characteristics, Genetics, and Progression.
Li CHZ; Pas JAAH; Corradi Z; Hitti-Malin RJ; Hoogstede A; Runhart EH; Dhooge PPA; Collin RWJ; Cremers FPM; Hoyng CB
Ophthalmology; 2024 Jan; 131(1):87-97. PubMed ID: 37598860
[TBL] [Abstract][Full Text] [Related]
20. Quantifying the Rate of Ellipsoid Zone Loss in Stargardt Disease.
Cai CX; Light JG; Handa JT
Am J Ophthalmol; 2018 Feb; 186():1-9. PubMed ID: 29126757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
